Compare AbbVie Inc (ABBV) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs SoundHound AI Inc — how do they compare? AbbVie Inc trades at $247.36 (market cap $441.94B), while SoundHound AI Inc trades at $7.37 (market cap $3.29B). The key difference: AbbVie Inc is far larger — about 134.3× SoundHound AI Inc's market cap, and AbbVie Inc pays a 2.77% dividend while SoundHound AI Inc pays none. Which is the better fit depends on your goals.
| ABBV | SOUN | |
|---|---|---|
Market Cap | $441.94B | $3.29B |
Sector | Health | Technology |
52-Week High | $263.58 | $21.40 |
52-Week Low | $197.38 | $5.70 |
Enterprise Value | $506.19B | $3.09B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
SoundHound AI (SOUN) trades at $7.395, down 0.87% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations, revenue grew 45% year-over-year to $61.9 million, and the company raised its 2026 revenue guidance, driven by its OASYS platform. However, the stock faces headwinds from negative net income margins and high cash burn.
The outlook is cautiously optimistic with 75% of analysts rating it Buy and a $8.50 consensus target, but profitability challenges and premium valuations pose risks. Key catalysts include the pending LivePerson acquisition and OASYS adoption, while execution on path to profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
